Biotech Values

[ghmm]

LGND:

Perhaps their single most valuable asset at this point is their NOL.

This is another reason I thought they would (should) raise some cash as the stock went up. If they want to be a meaningful royalty company I thought they needed a much stronger balance sheet to do deals (and thus generate meaningful revenue to take advantage of the NOL's) instead of their (granted very creative) deals the past couple years. Still I wonder how much of their NOL's will expire.

When I first bought the stock I had hopes the promacta follow-on would be advanced and could become very meaningful especially if it was safer (in addition to being more potent) but GSK not advancing it makes me wonder if it will ever see the light of day.